The stock price of Protagenic Therapeutics Inc (NASDAQ: PTIX) has dropped by -11.77 compared to previous close of 0.37. Despite this, the company has seen a gain of 5.64% in its stock price over the last five trading days. accesswire.com reported 2024-11-05 that NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) (“Protagenic Therapeutics” or the “Company”), a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced private placement pursuant to a purchase agreement (the “Purchase Agreement”) for the purchase and sale of an aggregate of 1,948,295 shares of common stock, series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date, and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants was $0.64 ($0.89 in the case of insiders).
Is It Worth Investing in Protagenic Therapeutics Inc (NASDAQ: PTIX) Right Now?
Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PTIX is 6.27M, and currently, short sellers hold a 1.72% ratio of that float. The average trading volume of PTIX on March 10, 2025 was 2.18M shares.
PTIX’s Market Performance
PTIX’s stock has seen a 5.64% increase for the week, with a -13.99% drop in the past month and a -41.50% fall in the past quarter. The volatility ratio for the week is 26.25%, and the volatility levels for the past 30 days are at 13.95% for Protagenic Therapeutics Inc The simple moving average for the past 20 days is 13.48% for PTIX’s stock, with a -51.47% simple moving average for the past 200 days.
PTIX Trading at -17.37% from the 50-Day Moving Average
After a stumble in the market that brought PTIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.77% of loss for the given period.
Volatility was left at 13.95%, however, over the last 30 days, the volatility rate increased by 26.25%, as shares surge +18.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.31% lower at present.
During the last 5 trading sessions, PTIX rose by +5.64%, which changed the moving average for the period of 200-days by -78.38% in comparison to the 20-day moving average, which settled at $0.2841. In addition, Protagenic Therapeutics Inc saw -34.24% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PTIX
Current profitability levels for the company are sitting at:
- -185.94 for the present operating margin
- -0.83 for the gross margin
The net margin for Protagenic Therapeutics Inc stands at -199.27. The total capital return value is set at -7.33. Equity return is now at value -231.87, with -162.74 for asset returns.
Currently, EBITDA for the company is -4.5 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 45.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.80.
Conclusion
To put it simply, Protagenic Therapeutics Inc (PTIX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
